A rendering of Amgen's new science and innovation center in Thousand Oaks. (courtesy photo) Thousand Oaks-based Amgen delivered a sound third-quarter earnings beat when it announced financial results on Nov. 4, highlighting big sales beats from blockbuster drugs Repatha and Prolia. Amgen, one of the largest biotechnology companies in the world, announced that revenue for…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
